CR20230024A - Derivados de quinoxalina como fármacos contra el cáncer - Google Patents
Derivados de quinoxalina como fármacos contra el cáncerInfo
- Publication number
- CR20230024A CR20230024A CR20230024A CR20230024A CR20230024A CR 20230024 A CR20230024 A CR 20230024A CR 20230024 A CR20230024 A CR 20230024A CR 20230024 A CR20230024 A CR 20230024A CR 20230024 A CR20230024 A CR 20230024A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cancer drugs
- quinoxaline derivatives
- quinoxaline
- derivatives
- drugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de azaquinolona de Fórmula (I), y a su uso en medicina. <img src="data:image/png;base64,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 (***)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063044095P | 2020-06-25 | 2020-06-25 | |
US202063120351P | 2020-12-02 | 2020-12-02 | |
PCT/EP2021/067304 WO2021260092A1 (en) | 2020-06-25 | 2021-06-24 | Quinoxaline derivatives as anti-cancer drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230024A true CR20230024A (es) | 2023-03-01 |
Family
ID=76662494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230024A CR20230024A (es) | 2020-06-25 | 2021-06-24 | Derivados de quinoxalina como fármacos contra el cáncer |
Country Status (19)
Country | Link |
---|---|
US (2) | US11795158B2 (es) |
EP (1) | EP4172152A1 (es) |
JP (1) | JP2023532257A (es) |
KR (1) | KR20230026450A (es) |
CN (1) | CN115768760A (es) |
AU (1) | AU2021295423B2 (es) |
BR (1) | BR112022025435A2 (es) |
CA (1) | CA3186996A1 (es) |
CL (1) | CL2022003711A1 (es) |
CO (1) | CO2023000186A2 (es) |
CR (1) | CR20230024A (es) |
DO (1) | DOP2022000288A (es) |
EC (1) | ECSP23005059A (es) |
IL (1) | IL299123A (es) |
MX (1) | MX2022015435A (es) |
PE (1) | PE20231081A1 (es) |
TW (1) | TW202218664A (es) |
UY (1) | UY39296A (es) |
WO (1) | WO2021260092A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220040173A1 (en) * | 2020-08-04 | 2022-02-10 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
JP2024514223A (ja) | 2021-04-19 | 2024-03-28 | シンセラ, インコーポレイテッド | Parp1阻害薬及びその使用 |
TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
JP2024519188A (ja) | 2021-05-24 | 2024-05-08 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 含窒素複素環系化合物、その調製方法及びその医薬的応用 |
CA3222841A1 (en) * | 2021-06-16 | 2022-12-22 | Cameron Black | Use of atr inhibitors in combination with parp inhibitors for treating cancer |
WO2022271547A1 (en) | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药(杭州)有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
WO2023051807A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 双环衍生物parp抑制剂及其用途 |
KR20240069791A (ko) | 2021-10-01 | 2024-05-20 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
AU2022390101A1 (en) | 2021-11-19 | 2024-06-06 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Selective parp1 inhibitor and application thereof |
WO2023118085A1 (en) * | 2021-12-21 | 2023-06-29 | Astrazeneca Ab | Methods of treating brain tumours and neuroblastomas |
WO2023134647A1 (zh) * | 2022-01-13 | 2023-07-20 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
WO2023138541A1 (zh) * | 2022-01-20 | 2023-07-27 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
WO2023141290A1 (en) | 2022-01-21 | 2023-07-27 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
WO2023146957A1 (en) * | 2022-01-27 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
WO2023146960A1 (en) * | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
EP4355749A1 (en) | 2022-04-28 | 2024-04-24 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
WO2023217045A1 (zh) * | 2022-05-07 | 2023-11-16 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
WO2023227052A1 (zh) * | 2022-05-25 | 2023-11-30 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
WO2023232069A1 (zh) * | 2022-06-02 | 2023-12-07 | 成都苑东生物制药股份有限公司 | 一种氮杂喹啉酮类衍生物、其制备方法及用途 |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
WO2024067691A1 (zh) * | 2022-09-30 | 2024-04-04 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
US20240174669A1 (en) * | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
WO2024121753A1 (en) | 2022-12-06 | 2024-06-13 | Astrazeneca Ab | Polq inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU691331B2 (en) | 1994-08-12 | 1998-05-14 | Myriad Genetics, Inc. | Method for diagnosing a predisposition for breast and ovarian cancer |
AU686004B2 (en) | 1994-08-12 | 1998-01-29 | Myriad Genetics, Inc. | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
PL2215075T3 (pl) | 2007-10-26 | 2014-04-30 | Janssen Pharmaceutica Nv | Pochodne chinolinonu jako inhibitory PARP |
EP2389379A1 (en) | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
CN107849040B (zh) | 2015-06-09 | 2021-04-06 | 肿瘤学治疗公司 | 三环衍生化合物、其制备方法、和含有其的药物组合物 |
US11325906B2 (en) | 2019-07-19 | 2022-05-10 | Astrazeneca Ab | Chemical compounds |
-
2021
- 2021-06-22 US US17/354,322 patent/US11795158B2/en active Active
- 2021-06-24 KR KR1020237001972A patent/KR20230026450A/ko active Search and Examination
- 2021-06-24 EP EP21735690.6A patent/EP4172152A1/en active Pending
- 2021-06-24 MX MX2022015435A patent/MX2022015435A/es unknown
- 2021-06-24 AU AU2021295423A patent/AU2021295423B2/en active Active
- 2021-06-24 BR BR112022025435A patent/BR112022025435A2/pt unknown
- 2021-06-24 CR CR20230024A patent/CR20230024A/es unknown
- 2021-06-24 CA CA3186996A patent/CA3186996A1/en active Pending
- 2021-06-24 PE PE2022002989A patent/PE20231081A1/es unknown
- 2021-06-24 JP JP2022579869A patent/JP2023532257A/ja active Pending
- 2021-06-24 WO PCT/EP2021/067304 patent/WO2021260092A1/en active Application Filing
- 2021-06-24 CN CN202180043057.8A patent/CN115768760A/zh active Pending
- 2021-06-24 IL IL299123A patent/IL299123A/en unknown
- 2021-06-25 UY UY0001039296A patent/UY39296A/es unknown
- 2021-06-25 TW TW110123282A patent/TW202218664A/zh unknown
-
2022
- 2022-12-14 DO DO2022000288A patent/DOP2022000288A/es unknown
- 2022-12-22 CL CL2022003711A patent/CL2022003711A1/es unknown
-
2023
- 2023-01-10 CO CONC2023/0000186A patent/CO2023000186A2/es unknown
- 2023-01-23 EC ECSENADI20235059A patent/ECSP23005059A/es unknown
- 2023-09-14 US US18/467,185 patent/US20240010631A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023532257A (ja) | 2023-07-27 |
PE20231081A1 (es) | 2023-07-17 |
DOP2022000288A (es) | 2023-01-15 |
KR20230026450A (ko) | 2023-02-24 |
US11795158B2 (en) | 2023-10-24 |
CO2023000186A2 (es) | 2023-04-17 |
UY39296A (es) | 2021-12-31 |
EP4172152A1 (en) | 2023-05-03 |
US20220009901A1 (en) | 2022-01-13 |
US20240010631A1 (en) | 2024-01-11 |
BR112022025435A2 (pt) | 2023-01-24 |
AU2021295423A1 (en) | 2023-02-16 |
AU2021295423B2 (en) | 2024-05-02 |
ECSP23005059A (es) | 2023-02-28 |
CA3186996A1 (en) | 2021-12-30 |
CN115768760A (zh) | 2023-03-07 |
CL2022003711A1 (es) | 2023-06-23 |
TW202218664A (zh) | 2022-05-16 |
MX2022015435A (es) | 2023-02-09 |
WO2021260092A1 (en) | 2021-12-30 |
IL299123A (en) | 2023-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022015435A (es) | Derivados de quinoxalina como farmacos anti-cancer. | |
CR20220070A (es) | Inhibidores de parp1 | |
PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
MD4584B1 (ro) | (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1ʹ,2ʹ:4,5]pirazino[2,1-b][1,3]oxazepin-8-olat de sodiu | |
MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
TR201819138T4 (tr) | FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
NZ710854A (en) | Quinolines derivatives as novel anticancer agents | |
PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
CO6511228A2 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
MA40583A (fr) | Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation | |
MX2013003635A (es) | Compuestos de n-heteroarilo. | |
AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
MX2022008478A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
MX2021010700A (es) | Compuestos utiles en la terapia del vih. | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
MX2011013869A (es) | Agentes antihelminticos y su uso. | |
SA520412155B1 (ar) | مشتقات إيميدازوبيريدين واستخدامها كدواء | |
MX2012007172A (es) | Piperazinas como agentes antimalaria. | |
MX2018015707A (es) | Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta. | |
MX2023000198A (es) | Inhibidores de atr y usos de estos. | |
WO2018178497A3 (es) | Uso de melatonina para el tratamiento de tumores |